1. Introduction

The Artificial Placenta Accountability Governance Doctrine is a proposed legal and ethical framework for determining responsibility, oversight, transparency, and remedies when artificial-placenta technology is developed, tested, or used in medical treatment.

An artificial placenta is an experimental technology intended to support extremely premature fetuses in a fluid-filled, womb-like environment, potentially allowing continued development outside the pregnant person's body. Related technologies are sometimes described as artificial wombs or extrauterine gestational systems. They are not necessarily interchangeable: some systems aim to support a fetus after very premature delivery, while a complete artificial womb would attempt to support development from an earlier stage.

The legal challenge is that these technologies may blur conventional distinctions between pregnancy, childbirth, neonatal intensive care, reproductive autonomy, and fetal treatment. Existing laws generally were not designed specifically for complete ectogenesis or artificial-placenta systems.

Important legal clarification: There is no universally recognized judicial doctrine formally called the “Artificial Placenta Accountability Governance Doctrine.” It is an analytical framework that can be constructed from established principles of medical negligence, product liability, informed consent, research ethics, constitutional rights, administrative oversight, and clinical-trial regulation.

This explanation uses relevant case law, particularly from India, the United States, the United Kingdom, and international human-rights jurisprudence. The cases establish transferable legal principles; they do not necessarily concern artificial placentas directly.

2. Meaning and essential elements of the doctrine

The doctrine asks a central question:

Who must answer for a decision, injury, malfunction, or rights violation involving an artificial-placenta system, and what legal remedies are available?

Its principal elements are:

Clinical accountability: Doctors and hospitals must justify decisions about whether the technology is appropriate, how it is operated, and how complications are managed.

Manufacturer accountability: Developers must adequately test the device, disclose known risks, provide reliable instructions, and monitor safety after deployment.

Research accountability: Investigators and sponsors must comply with clinical-trial safeguards, ethical review, and applicable rules governing fetal and neonatal research.

Parental and patient rights: Pregnant patients and parents must receive understandable information and meaningful opportunities to participate in decisions, subject to the law governing the patient's status and the child's interests.

Regulatory accountability: Public authorities must establish appropriate safety standards, supervise trials, investigate serious incidents, and provide reviewable reasons for consequential decisions.

Data and algorithmic accountability: Where the system uses sensors, predictive software, or automated adjustments, the parties responsible must be able to explain material decisions, preserve records, and investigate failures.

Remedial accountability: Injured patients or children must have access to appropriate compensation, corrective action, independent investigation, and judicial or administrative review.

These elements are interconnected. A manufacturer may be responsible for a defective sensor, a hospital for failing to maintain it, and a clinician for ignoring an alarm. Liability depends on the evidence, applicable law, causation, and each party's duty of care.

3. Major legal issues in artificial-placenta governance

A. Medical negligence and the duty of care

Artificial-placenta treatment would involve complex clinical decisions, including patient selection, transfer from conventional neonatal care, monitoring of circulation and oxygenation, infection prevention, emergency intervention, and decisions to continue or discontinue support.

A healthcare professional's liability may arise if the professional fails to meet the applicable standard of care and that failure causes legally recognized harm.

Relevant case: Dr. Laxman Balkrishna Joshi v. Dr. Trimbak Bapu Godbole, AIR 1969 SC 128.

Indian Kanoon

The Supreme Court of India identified duties owed by a medical practitioner in deciding whether to undertake a case, deciding what treatment to give, and administering that treatment. The judgment supplies a foundational framework for evaluating professional negligence.

Application: If a physician chooses an unsuitable candidate for artificial-placenta treatment, fails to respond to a known alarm, or operates equipment without appropriate competence, a court could examine whether the relevant duty of care was breached. The technology's novelty would not automatically excuse negligent conduct.

However, an adverse outcome alone does not establish negligence. The claimant must satisfy the applicable legal requirements, including causation and damage.

B. Informed consent and reproductive autonomy

Consent is especially important because artificial-placenta research may involve both a pregnant patient undergoing an intervention and a fetus or premature infant receiving experimental support.

The consent process should explain, in comprehensible language:

The experimental or established status of the technology.

Known risks, uncertainties, and possible long-term developmental effects.

Available conventional treatments and their respective risks.

The possibility that the device may fail or require emergency intervention.

The rules governing withdrawal from research and continued clinical care.

How medical records and biological data will be used.

Consent must be distinguished from parental permission for a child and from authorization for an intervention on a pregnant patient. These are related but legally distinct questions.

Relevant case: Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1.

Indian Kanoon

The Supreme Court of India emphasized the importance of valid consent before medical treatment. Consent to one procedure does not ordinarily authorize a materially different procedure merely because a doctor considers the additional intervention beneficial, subject to recognized emergency exceptions.

Application: Consent to an emergency delivery would not automatically establish consent to enrolment in an experimental artificial-placenta trial. Where circumstances permit, investigators should obtain specific informed consent for the research intervention and explain the distinction between research and ordinary treatment.

A further difficulty arises when delivery is urgent and the pregnant patient is incapacitated. Researchers and clinicians must follow the applicable emergency and research-consent rules rather than assume that parental agreement alone resolves every legal question.

C. Product liability and device safety

Artificial-placenta systems may contain pumps, oxygenators, vascular cannulas, fluid circuits, temperature controls, sensors, alarms, and software. Each component may introduce a distinct category of risk.

Potential legal claims include:

Design defect: The device is inherently unsafe for its intended use.

Manufacturing defect: A particular unit deviates from approved specifications.

Failure to warn: Important risks or limitations were inadequately disclosed.

Negligent maintenance: The hospital fails to inspect, service, or replace equipment properly.

Software or cybersecurity failure: A malfunction or unauthorized change disrupts safe operation.

Responsibility may be shared between manufacturers, hospitals, clinicians, and other suppliers. It depends on the applicable statutory regime, contractual arrangements, evidence of fault, and causal connection to the injury.

A product's regulatory authorization would be important evidence of compliance but would not necessarily immunize its manufacturer or user from liability for subsequent negligence or a defective product.

D. Research ethics and the experimental-treatment boundary

A central governance question is whether artificial-placenta use constitutes innovative clinical treatment or human-subject research.

The distinction matters because research may require ethics-committee review, regulatory authorization, a research protocol, specified eligibility criteria, safety monitoring, and additional protections for participants.

The article Artificial womb technology and clinical translation: Innovative treatment or medical research? argues that experimental artificial-womb systems should not be introduced into human care merely by describing them as beneficial innovation. The investigational character of the intervention requires appropriate research safeguards.

PubMed

A responsible trial should have:

A defensible scientific rationale and adequate preclinical evidence.

Independent ethical and regulatory review.

Clear inclusion and exclusion criteria.

A comparison with the best available standard of care.

Independent safety monitoring and predefined stopping rules.

Transparent reporting of adverse events and results.

Appropriate arrangements for follow-up and research-related injury.

The fact that a technology could eventually save lives does not itself establish that its risks are acceptable for a first-in-human trial.

4. Important case laws and their application

The following cases are not artificial-placenta decisions. They provide legal principles that courts and regulators may apply by analogy.

1. Bolam v. Friern Hospital Management Committee [1957] 1 WLR 582 — professional standard of care

The English court considered the standard against which a medical professional's conduct should be assessed, giving importance to a responsible body of professional opinion.

Relevance: In an artificial-placenta negligence claim, expert evidence may help establish what a reasonably competent practitioner should have done in the circumstances. Because the technology is novel, courts would need to assess the quality, applicability, and scientific basis of the professional opinion offered. The case does not mean that any professional practice endorsed by some experts is automatically lawful in every jurisdiction.

2. Montgomery v. Lanarkshire Health Board [2015] UKSC 11 — disclosure of material risks

The UK Supreme Court emphasized a patient's right to be informed of material risks and reasonable alternative treatments.

Relevance: Artificial-placenta consent cannot be reduced to a signed form. Information about material risks, uncertainty, conventional alternatives, and the consequences of choosing or declining the intervention should be discussed in a manner appropriate to the decision-maker's circumstances.

The precise legal test for disclosure varies between jurisdictions.

3. Airedale NHS Trust v. Bland [1993] AC 789 — withdrawal of life-sustaining treatment

The House of Lords considered the withdrawal of life-sustaining treatment from a patient in a persistent vegetative state.

Relevance: Artificial-placenta systems may raise difficult questions when continued support appears futile, causes disproportionate burdens, or conflicts with a patient's best interests. Decisions to discontinue support would require a legally appropriate clinical process and cannot be based solely on financial considerations or the convenience of the institution.

The case did not concern an artificial placenta or a fetus supported ex utero. Its application is therefore analogical, and the relevant rules governing newborns and end-of-life decisions must be considered separately.

4. Common Cause v. Union of India, (2018) 5 SCC 1 — dignity and end-of-life decisions

The Supreme Court of India recognized constitutional protection for dignity in dying and addressed advance directives and the withdrawal or withholding of life-sustaining medical treatment under specified safeguards.

Relevance: The judgment may inform discussions about dignity, treatment burdens, and lawful end-of-life decision-making in artificial-placenta care. It does not establish an unrestricted right to discontinue support for a fetus or premature infant, and its principles must be applied consistently with the legal status and best interests of the child.

5. Jacobson v. Massachusetts, 197 U.S. 11 (1905) — public-health authority and limits

The US Supreme Court upheld a state's vaccination requirement in the public-health circumstances before it.

Relevance: The case illustrates that medical regulation may legitimately protect public welfare. It does not authorize unlimited state control over reproductive decisions. Any regulatory restriction on artificial-placenta treatment must still comply with the constitutional and statutory requirements of the jurisdiction concerned.

6. Maneka Gandhi v. Union of India, (1978) 1 SCC 248 — fairness in state action

The Supreme Court of India developed the principle that state action affecting personal liberty must satisfy applicable requirements of fairness, non-arbitrariness, and constitutional due process.

Relevance: If a public regulator suspends an artificial-placenta programme, refuses authorization, or imposes restrictive conditions, its decision may be subject to judicial review under the applicable law. The regulator should act within its authority and provide legally sufficient reasons and procedures where required.

7. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1 — privacy and informational autonomy

The Supreme Court of India recognized privacy as a fundamental right under the Constitution.

Relevance: Artificial-placenta systems could collect highly sensitive information, including physiological measurements, genetic information, developmental data, and family medical records. Data collection, access, retention, disclosure, and secondary research use must be evaluated under applicable privacy and data-protection law.

Privacy rights do not, by themselves, resolve every question about fetal status, parental access, or research use. Those questions require a more specific legal analysis.

5. Indian statutory and regulatory framework

India does not have a dedicated, comprehensive statute specifically governing artificial-placenta technology. Depending on the device's design, intended use, and research protocol, several existing legal frameworks may become relevant.

A. Medical Devices Rules, 2017

These rules provide the framework for regulating medical devices in India, including applicable requirements relating to manufacture, import, licensing, and quality. An artificial-placenta system would require classification and regulatory assessment according to its characteristics and intended use.

Directorate General of Health Services

+1

B. New Drugs and Clinical Trials Rules, 2019

These rules establish requirements for covered clinical trials and ethics committees. Rule 15 and related provisions address ethics review and oversight of biomedical and health research. Their precise application depends on whether the proposed investigation falls within the relevant statutory categories.

CDSCO

+1

C. Constitutional law

Articles 14 and 21 of the Constitution of India may be relevant to non-arbitrary public regulation, personal liberty, dignity, and bodily autonomy. Their application depends on the circumstances, including whether the challenged action is attributable to the State and what rights are engaged.

D. Consumer protection and civil liability

The Consumer Protection Act, 2019, applicable tort principles, and relevant product-liability provisions may provide remedies where their legal conditions are satisfied. Contractual obligations, professional standards, and other applicable statutes may also be relevant.

The Central Drugs Standard Control Organisation (CDSCO) is India's central authority for specified medical-product and clinical-trial regulatory functions. Its responsibilities include relevant medical-device regulation and oversight of covered clinical trials.

Directorate General of Health Services

+1

6. The accountability governance model

A practical artificial-placenta governance doctrine should distribute responsibility across the entire technology lifecycle rather than placing it solely on the treating doctor.

These categories are not mutually exclusive. For example, a preventable injury caused by an inadequately tested pump could involve manufacturer liability, deficient hospital maintenance, and a failure by clinical staff to respond appropriately.

A proposed five-stage accountability test

Authorization: Was the device or investigation lawfully authorized, and were required ethics approvals obtained?

Informed decision-making: Were the relevant patient, parental, and research-consent requirements satisfied?

Safe operation: Were appropriate clinical standards, monitoring procedures, staffing arrangements, and emergency plans followed?

Traceability: Were device settings, alarms, clinical decisions, software changes, adverse events, and corrective actions documented?

Remedy and review: Was the incident investigated independently where appropriate, and were compensation, corrective action, or judicial review available under applicable law?

This five-stage test is a proposed analytical model, not an existing statutory test or a binding rule laid down by a court.

7. Difficult legal questions

A. Who has legal authority to make treatment decisions?

An artificial-placenta patient occupies a medically unusual position: the subject may have been delivered from the uterus but still require support intended to maintain fetal physiology.

The law must distinguish the legal status of the child from the physiological characteristics of the technology. The fact that development continues in an external system should not, by itself, determine whether the subject has legal personhood or which protections apply.

B. Can parents demand continued artificial-placenta support?

Parental authority is important, but it is not necessarily absolute. The treating team must consider the child's best interests, the expected benefits and burdens of treatment, relevant professional standards, and applicable law.

Where there is serious disagreement about withdrawing or continuing support, an independent clinical review and, where necessary, judicial determination may be appropriate. A decision should not rest solely on cost, institutional convenience, or an unsupported assumption about disability.

C. Who is liable when an automated system fails?

Suppose an oxygenation sensor produces an incorrect reading and software reduces support to a dangerously low level. A proper investigation would examine:

Whether the sensor was defective or inadequately validated.

Whether the software was appropriately tested for the intended clinical environment.

Whether the hospital followed maintenance and calibration requirements.

Whether clinicians received and responded to relevant alarms.

Whether the failure caused the injury.

Automated decision-making does not eliminate human or institutional accountability. Equally, a clinician should not automatically be blamed for a failure that could not reasonably have been detected or prevented.

D. How should long-term harm be addressed?

An artificial-placenta intervention may have consequences that are not immediately apparent, including developmental complications. Responsible governance therefore requires appropriate long-term follow-up, transparent communication of emerging risks, and clear arrangements for research-related injury and continuing care.

The exact duration and scope of follow-up should be scientifically justified and ethically reviewed.

8. International ethical developments

Artificial-placenta governance is an active subject of legal and bioethical research.

A 2025 systematic review published in Prenatal Diagnosis identified disputes concerning moral status, reproductive autonomy, and the ethical conditions for human research. It also cautioned that discussion of hypothetical complete artificial gestation can overshadow the nearer-term objective of supporting extremely premature infants.

PubMed

+1

A scoping review published in the Journal of Perinatology on 13 April 2026 examined 247 publications and identified recurring issues involving benefits and harms, decision-making, legal and moral status, justice, research ethics, and oversight.

Journal of Perinatology

These publications are scholarly analyses, not binding legal authorities. They nevertheless support the need for governance that is proportionate to the actual clinical application rather than based entirely on speculation about future reproductive technologies.

9. Proposed reforms

A comprehensive regulatory framework should include the following measures:

Specific regulatory classification: Clarify the approval pathway for artificial-placenta systems, including integrated hardware, software, and life-support components.

Mandatory independent review: Require appropriate independent ethics review and regulatory authorization before covered human investigations begin.

Enhanced consent safeguards: Develop consent procedures suitable for urgent delivery, maternal incapacity, and research involving premature infants.

Incident reporting: Establish clear requirements for reporting device failures, serious adverse events, and unexpected outcomes.

Independent safety oversight: Require predefined stopping rules and periodic review of emerging evidence.

Long-term monitoring: Establish appropriate developmental follow-up and transparent publication of trial results.

Clear liability rules: Clarify the responsibilities of manufacturers, hospitals, clinicians, sponsors, and software providers.

Equitable access: Prevent unjustified discrimination based on disability, socioeconomic status, or other legally protected characteristics.

Judicial and administrative review: Ensure that regulatory decisions can be challenged through applicable legal procedures.

Periodic legislative review: Update the framework as clinical evidence and the technology's intended uses evolve.

10. Conclusion

The Artificial Placenta Accountability Governance Doctrine is best understood as a proposed framework for applying established legal principles to an emerging form of life-support technology.

Its foundation lies in medical negligence, informed consent, product safety, research ethics, privacy, constitutional rights, and accountable regulation. The cases discussed above offer important guidance, particularly Laxman Balkrishna Joshi on professional duties, Samira Kohli on consent, Montgomery on material risks, and Common Cause on dignity and end-of-life safeguards.

However, no cited case establishes a dedicated legal doctrine governing artificial placentas. The framework must therefore be applied carefully, with attention to the actual clinical use, the subject's legal status, applicable statutory requirements, and the facts of each dispute.

The ultimate governance objective is to ensure that technological innovation does not weaken established protections for patients, children, families, or research participants—and that every consequential clinical, technical, and regulatory decision remains open to appropriate scrutiny and accountability.

Academic note: This is a general research explanation, not a jurisdiction-specific legal opinion. Before relying on any authority in litigation or formal academic submission, verify the full judgment, current statutory text, and the relevant regulatory classification.